Search | Clinical Trials Finder

Conditions: Asthma
Interventions: Ciclesonide, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 4 Years to 11 Years
Enrollment: 528 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Status Asthmaticus
Interventions: Montelukast Oral Granules, Albuterol, Corticosteroid; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 4 Years to 12 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Chronic Obstructive Airways Disease Exacerbated, Chronic Obstructive Airway Disease
Interventions: Digital Inhaler Attachment; Device
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Aclidinium/formoterol 400/12μg, Formoterol; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Spartanburg, South Carolina

Conditions: Eosinophilic Asthma, Severe Asthma, Severe Eosinophilic Asthma, Asthma
Interventions: Budesonide-albuterol, Benralizumab; Drug
Lead sponsor: Endeavor Health; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Skokie, Illinois

Conditions: Anxiety, Panic Attacks
Interventions: CalmiGo; Device
Lead sponsor: Yves Duroseau; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Manhattan, New York

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Batefenterol, Umeclidinium/ Vilanterol, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 9
States / cities: Hialeah, Florida • Baltimore, Maryland • St Louis, Missouri + 6 more

Conditions: Asthma
Interventions: Treatment A: Fp MDPI, Treatment B: FS MDPI, Treatment C Flovent, Treatment D: Advair; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 3
States / cities: Raleigh, North Carolina • Edmond, Oklahoma • San Antonio, Texas

Conditions: Asthma
Interventions: Budesonide HFA, Budesonide CFC; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: King of Prussia, Pennsylvania

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: olodaterol, tiotropium, placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 809 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 20
States / cities: Jasper, Alabama • Stamford, Connecticut • Clearwater, Florida + 17 more

Conditions: Exercise-induced Bronchospasm
Interventions: arformoterol, formoterol, placebo; Drug
Lead sponsor: University of New Mexico; Other
Eligibility: 12 Years to 17 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Asthma
Interventions: Budesonide/formoterol fumarate Aerosphere, Budesonide/formoterol fumarate pMDI; Combination Product
Lead sponsor: AstraZeneca; Industry
Eligibility: 4 Years to 12 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 6
States / cities: Long Beach, California • Miami, Florida • Lafayette, Louisiana + 3 more

Conditions: COPD
Interventions: Not listed
Lead sponsor: COPD Foundation; Other
Eligibility: 60 Years to 90 Years
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 9
States / cities: Birmingham, Alabama • Chicago, Illinois • Burlington, Massachusetts + 6 more

Conditions: Smoking Cessation
Interventions: Non-flavored 2mg nicotine gum, Non-flavored 4mg nicotine gum, Mint-flavored 2mg nicotine gum, Mint-flavored 4mg nicotine gum, Non-flavored nicotine inhaler, Mint-flavored nicotine ihaler; Other
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Type 2 Diabetes Mellitus
Interventions: Technosphere® Insulin Inhalation Powder and MedTone™ Inhaler; Drug
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 17
States / cities: San Mateo, California • Santa Barbara, California • Middlebury, Connecticut + 12 more

Conditions: Pulmonary Hypertension, Interstitial Lung Disease
Interventions: Treprostinil Palmitil Inhalation Powder, Placebo; Drug
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 11
States / cities: Los Angeles, California • Santa Barbara, California • Gainesville, Florida + 8 more

Conditions: COPD
Interventions: Indacaterol, Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 40 Years and older
Enrollment: 415 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 93
States / cities: Homewood, Alabama • Jasper, Alabama • Phoenix, Arizona + 83 more

Conditions: Asthma in Children, Nonadherence, Medication
Interventions: Maintenance ICS and Symptom Driven SABA, Symptom-driven budesonide/formoterol combination; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 12 Years to 17 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Healthy Volunteers, Alzheimer Disease
Interventions: ALZT-OP1 (cromolyn and ibuprofen) ALZT-OP1a (cromolyn) and ALZT-OP1b (ibuprofen); Drug
Lead sponsor: AZTherapies, Inc.; Industry
Eligibility: 55 Years to 79 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Miami Lakes, Florida

Conditions: Asthma
Interventions: Fp MDPI, Flovent Diskus, albuterol/salbutamol, Placebo MDPI; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 909 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 129
States / cities: Homewood, Alabama • Goodyear, Arizona • Scottsdale, Arizona + 104 more

Conditions: Agitation,Psychomotor, Haloperidol Causing Adverse Effects in Therapeutic Use, Lorazepam Causing Adverse Effects in Therapeutic Use, Loxapine Causing Adverse Effects in Therapeutic Use
Interventions: Haloperidol + lorazepam, Loxapine; Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 65 Years
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Nicotine Dependence
Interventions: Varenicline, Bupropion, Nicotine patches, Nicotine Inhaler; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 702 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 4
States / cities: Charlotte, North Carolina • Durham, North Carolina • Raleigh, North Carolina + 1 more

Conditions: Healthy Participants
Interventions: Treatment A: BGF MDI HFO, Treatment B: BGF MDI HFA; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 105 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Asthma
Interventions: Beclomethasone dipropionate BAI, Placebo BAI, albuterol/salbutamol 90 mcg, Beclomethasone dipropionate MDI, Placebo MDI; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 4 Years to 11 Years
Enrollment: 628 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 75
States / cities: Hoover, Alabama • Montgomery, Alabama • Phoenix, Arizona + 62 more

Search by objective public record fields.

Efficacy and Safety of Ciclesonide (CIC) Administered Twice Daily in Pediatric Patients With Asthma.

Treating Exacerbations of Asthma With Oral Montelukast in Children

Digital Inhaler Use in Obstructive Lung Disease Care

Pharmacokinetic, Safety and Tolerability Study of Aclidinium/Formoterol Fixed Dose Combination and Formoterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Fasenra: An Asthma Study

Using CalmiGo to Manage Anxiety and Panic Attack Symptoms in the Emergency Department

Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Study to Determine the Pharmacokinetics and Tolerability of Fluticasone Propionate MDPI and Fluticasone Propionate/Salmeterol MDPI Compared to High Strength FLOVENT® DISKUS® and ADVAIR® DISKUS® in Patients With Persistent Asthma 12 Years of Age and Older

Study Comparing Budesonide Hydrofluoroalkane (HFA) vs Chlorofluorocarbon (CFC) Pressurized Metered Dose Inhalers (pMDI) in Patients With Mild to Moderate Asthma

Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)

Bronchoprotective Effect of Arformoterol in Children With Exercise-Induced Bronchospasm (EIB)

A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Different Devices in Participants Aged 4 to Less Than 12 Years Old With Asthma

Impairments That Affect Correct Inhaler Use in COPD

Evaluation of Cessation Preferences of Menthol Smoker

An Open-label, Multi-center, International, Three-year, Safety and Tolerability 'Follow on' Trial

Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Safety, Tolerability and Efficacy of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

Symptom-driven ICS/LABA Therapy for Adolescent Patients With Asthma Non-adherent to Daily Maintenance Inhalers

Randomized I/II Phase Study of ALZT-OP1 Combination Therapy in Alzheimer's Disease and Normal Healthy Volunteers

A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler in Adolescents and Adults Who Have Asthma That is Not Controlled by Asthma Medications Not Containing Steroids

Inhaled Loxapine vs Intramuscular (IM) Haloperidol + Lorazepam for Agitation

Concurrent Bupropion / Varenicline for Smoking Cessation

A Study to Investigate the Exposure of Budesonide, Glycopyrronium, and Formoterol (BGF) Delivered by Hydrofluoroolefin (HFO) Propellant Metered Dose Inhaler (MDI) Compared to a Hydrofluoroalkane (HFA) Propellant MDI in Healthy Adults

A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants Ages 4-11 Years Old With Persistent Asthma